IDEXX Laboratories, Inc. vs M&T Bank Corporation — how do they compare? IDEXX Laboratories, Inc. trades at $512.76 (market cap $40.43B), while M&T Bank Corporation trades at $222.43 (market cap $31.42B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and M&T Bank Corporation pays a 2.76% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and M&T Bank Corporation for 100 Days on average.
| IDXX | MTB | |
|---|---|---|
Market Cap | $40.43B | $31.42B |
Volume | 692,164 | 1,438,219 |
Sector | Health | Financials |
52-Week High | $766.68 | $254.09 |
52-Week Low | $504.70 | $178.63 |
Typical Hold Time | 46 Days | 100 Days |
Enterprise Value | $41.32B | $47.77B |
Dividend Yield | — | 2.76% |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $506.67, down 1.7% on the day, with technical indicators showing bearish momentum despite strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $4.27 exceeding expectations of $3.94. Recent developments include the acquisition of CoVetAI to enhance veterinary workflow intelligence and expansion of diagnostic testing platforms internationally. Revenue growth remains robust at $4.3 billion for 2025, with net income margins exceeding 25%.
The stock presents a compelling growth story with strong profitability metrics and analyst consensus pointing to significant upside potential (average price target $665). However, current technical weakness and premium valuations (P/E 36.06) create near-term headwinds. Key risks include foreign exchange pressures and potential slowdown in U.S. veterinary visits, while institutional ownership trends show mixed positioning among major funds.
M&T Bank Corporation (MTB) trades at $216.6, down 0.98% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The bank maintains strong profitability with a 30.85% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights loan growth, AI investments, and a new branch opening, while the company declared a $1.50 dividend payable in September 2026.
The outlook is mixed: analyst consensus is a 'Buy' with a $258.92 price target implying 19.5% upside, but technical weakness and a high proportion of 'Hold' ratings suggest caution. Key risks include volatile cash flows, with a net outflow of $2.01B in 2025, and sensitivity to interest rate changes. Earnings momentum from loan growth and technology investments supports potential recovery.
Trailing returns across standard periods
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →